← brief for 2026-08-26 · Slowing decline

Glucagon-Like Peptide-1 Receptor Agonist Use and Risks of Hospitalization and Mortality in Patients with End-Stage Kidney Disease.

Key takeaways

Researchers looked at records of people who had just reached kidney failure and needed dialysis, comparing those taking GLP-1 drugs like semaglutide with those who were not. The people on these drugs went to hospital less often and were less likely to die. This is a look back at existing records, so it shows a link, not proof that the drug caused the benefit: people prescribed these drugs may be healthier to begin with. It matters because the big FLOW trial that proved semaglutide helps kidneys left out people already on dialysis.

Who did this work

Karpinski S · Qazi R · Bjordahl T · Sibbel S · Weinhandl E · Tentori F · Brunelli SM

Source

Article · PubMed, the drug frontier · 2026 Aug 25
https://pubmed.ncbi.nlm.nih.gov/42640716/